147388-83-8
中文名称
3-甲基-5-[(2S)-1-甲基-2-吡咯烷基]异恶唑盐酸盐
英文名称
ABT-418 HYDROCHLORIDE
CAS
147388-83-8
分子式
C9H14N2O.ClH
分子量
202.684
MOL 文件
147388-83-8.mol
147388-83-8 结构式
基本信息
中文别名
3-甲基-5-[(2S)-1-甲基-2-吡咯烷基]异恶唑盐酸盐 英文别名
ABT-418 HClABT-418 HYDROCHLORIDE
(S)-3-Methyl-5-(1-methylpyrrolidin-2-yl)-isoxazolea€¢HCl
3-Methyl-5-[(2S)-1-Methylpyrrolidin-2-yl]isoxazole hydrochloride
物理化学性质
储存条件-20°C
溶解度H2O: 15 mg/mL, soluble
形态solid
颜色white to off-white
水溶解性H2O: soluble 15mg/mL
稳定性自购买之日起 1 年内保持稳定。蒸馏水溶液可在 -20°C 下保存长达 3 个月。
InChI1S/C9H14N2O.ClH/c1-7-6-9(12-10-7)8-4-3-5-11(8)2;/h6,8H,3-5H2,1-2H3;1H/t8-;/m0./s1
InChIKeyVOXHERKWAIEJQF-QRPNPIFTSA-N
SMILESCl.CN1CCC[C@H]1c2cc(C)no2
安全数据
警示词危险
危险性描述H300+H310+H330
危险品标志T+
危险类别码26/27/28
危险品运输编号UN 2811 6.1/PG 1
WGK Germany3
存储类别6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials
very toxic hazardous materials
危险性类别Acute Tox. 2 Dermal
Acute Tox. 2 Inhalation
Acute Tox. 2 Oral
Acute Tox. 2 Inhalation
Acute Tox. 2 Oral
3-甲基-5-[(2S)-1-甲基-2-吡咯烷基]异恶唑盐酸盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-105170B | 3-甲基-5-[(2S)-1-甲基-2-吡咯烷基]异恶唑盐酸盐 ABT-418 hydrochloride | 147388-83-8 | 1 mg | 545元 |
| 2025/12/22 | HY-105170B | 3-甲基-5-[(2S)-1-甲基-2-吡咯烷基]异恶唑盐酸盐 ABT-418 hydrochloride | 147388-83-8 | 5mg | 1200元 |
| 2025/12/22 | HY-105170B | 3-甲基-5-[(2S)-1-甲基-2-吡咯烷基]异恶唑盐酸盐 ABT-418 hydrochloride | 147388-83-8 | 10mM * 1mLin Water | 1320元 |
常见问题列表
生物活性
ABT-418 hydrochloride 是一种高效、选择性的 nAChRs 激动剂,具有增强认知和抗焦虑的作用。ABT-418 hydrochloride 激活胆碱能通道,可用于阿尔茨海默病的研究。靶点
nAChRs
体内研究
ABT-418 hydrochloride (125.66 μg/kg; i.p.) induces a significant increase in the time spent by the rats in the open arms of the elevated plus maze.
Acute administration of ABT-418 (125.66μg/kg; i.p.) also attenuates the anxiogenic-like effect elicited by withdrawal from chronic (-)-nicotine treatment.
ABT-418 hydrochloride (0.6 mg/kg; i.p.; daily; for two weeks) effectively improves spatial memory in an animal model of ADHD.
ABT-418 hydrochloride significantly enhances the cortical α4 and β2 nAChR subunits and the hippocampal α4 subunit expression.
| Animal Model: | Male SHRs (4–5 weeks old), attention deficit hyperactivity disorder (ADHD) model |
| Dosage: | 0.6 mg/kg |
| Administration: | Intraperitoneal injection; once daily; for two weeks |
| Result: | Effectively improved spatial memory. |
